Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities

Nehemias Guevara, Syeda Ashna Fatima Kamal, Noemy Coreas, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 2206.

https://doi.org/10.1182/blood-2025-2206

Published: 2025

Journal Articles

Disproportionate risk of hematologic malignancies in sickle cell disease (SCD) across age strata: A multicenter matched cohort analysis

Nehemias Guevara, Syeda Ashna Fatima Kamal, Noemy Coreas, Ashley Ellis, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 41.

https://doi.org/10.1182/blood-2025-41

Published: 2025

Journal Articles

Emergency presentation worsens survival, complications, and reveals profound disparities in acute lymphoblastic leukemia: A national propensity-matched study

Nehemias Guevara, Syeda Ashna Fatima Kamal, Noemy Coreas, Brian Abboud, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 5096.

https://doi.org/10.1182/blood-2025-5096

Published: 2025

Journal Articles

Acrobat interim results: Alloheme surveillance enables early detection of relapse in post-HCT AML and MDS patients

Monzr M. Al Malki, Corey Cutler, Ronald Sobecks, Iskra Pusic, Nelli Bejanyan, Sagar Patel, Arpita Gandhi, Vamsi Kota, Nabeel Rajeh, Piyanuch Kongtim, Chun-Po Fan, Yangyang Hao, Evgeniya Vaskova, Natali Gulbahce, Ashish Kothari, Nishant Dwivedi, Robert Woodward, Ran Reshef, Stefan Ciurea

Blood (2025) 146 (Supplement 1): 4301.

https://doi.org/10.1182/blood-2025-4301

Published: 2025

Journal Articles

Emergency department presentation is an independent driver of mortality, complications, and disparities in Acute Myeloid Leukemia: A national propensity-matched Study

Syeda Ashna Fatima Kamal, Nehemias Guevara, Noemy Coreas, Brian Abboud, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 448.

https://doi.org/10.1182/blood-2025-448

Published: 2025

Journal Articles

Is hydroxyurea treatment associated with an increased risk of malignancy in sickle cell disease? a propensity-matched analysis of 27,854 patients in the real world

Syeda Ashna Fatima Kamal, Nehemias Guevara, Noemy Coreas, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 1178.

https://doi.org/10.1182/blood-2025-1178

Published: 2025

Journal Articles

IVIG prevents infections without affecting mortality in DLBCL patients treated with CAR T-cell or bispecific antibody therapy: A real-world propensity-matched study

Nehemias Guevara, Syeda Ashna Fatima Kamal, Nisheem Pokharel, Pravash Budhathoki, Noemy Coreas, Nabeel Rajeh, Ranju Kunwor

Blood (2025) 146 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2025-1886

Published: 2025

Journal Articles

Does Cytokine Release Syndrome Predict Cancer Remission within 30 Days Following Chimeric Antigen Receptor T-Cell Therapy?

Nada Al Masalmeh, Mahta Salehi, Arslan Barbar, Jason Doherty, Nabeel Rajeh, Ranju Kunwor

Blood (2024) 144 (Supplement 1): 6547.

https://doi.org/10.1182/blood-2024-199380

Published: 2024

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Surviving Stem Cell Transplantation Program In War Time In Syria

Nabeel Rajeh, MD, Maha Manchi, Seham Suliman, Zahera Fahed, Muhamad Barali, Muhamad Kalta

Blood (2013) 122 (21): 5525.

https://doi.org/10.1182/blood.V122.21.5525.5525

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities

Disproportionate risk of hematologic malignancies in sickle cell disease (SCD) across age strata: A multicenter matched cohort analysis

Emergency presentation worsens survival, complications, and reveals profound disparities in acute lymphoblastic leukemia: A national propensity-matched study

Acrobat interim results: Alloheme surveillance enables early detection of relapse in post-HCT AML and MDS patients

Emergency department presentation is an independent driver of mortality, complications, and disparities in Acute Myeloid Leukemia: A national propensity-matched Study

Is hydroxyurea treatment associated with an increased risk of malignancy in sickle cell disease? a propensity-matched analysis of 27,854 patients in the real world

IVIG prevents infections without affecting mortality in DLBCL patients treated with CAR T-cell or bispecific antibody therapy: A real-world propensity-matched study

Does Cytokine Release Syndrome Predict Cancer Remission within 30 Days Following Chimeric Antigen Receptor T-Cell Therapy?

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Surviving Stem Cell Transplantation Program In War Time In Syria

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only